Year archive

Lonza Group AG — 2023 filings

All 36 regulatory filings released by Lonza Group AG (LONN) in 2023, sourced directly from the official regulator.

36 Filings

2023 Period

2023 filings (36)

Filing	Released	Lang
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds Capital/Financing Update	2023-11-06	English
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds Capital/Financing Update	2023-11-06	English
Capital Markets Day 2023: New Mid-Term Guidance 2024 2028 Supported by Ramp-Up of Growth Projects Investor Presentation	2023-10-17	English
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects Regulatory Filings	2023-10-17	English
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer Regulatory Filings	2023-10-13	English
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer Regulatory Filings	2023-10-13	English
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023 Report Publication Announcement	2023-09-21	English
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023 Report Publication Announcement	2023-09-21	English
Board Announcement Board/Management Information	2023-09-18	English
Board Announcement Board/Management Information	2023-09-18	English
Mitteilung des Verwaltungsrats Board/Management Information	2023-09-18	German
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin Earnings Release H1 2023	2023-07-21	English
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin Earnings Release H1 2023	2023-07-21	English
Lonza erzielt ein Umsatzwachstum von 5.6% (kWk) mit zugrunde liegendem Wachstum von rund 10% (kWk) und eine Kern-EBITDA-Marge von 30% Earnings Release H1 2023	2023-07-21	German
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering M&A Activity	2023-06-01	English
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering M&A Activity	2023-06-01	English
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory Earnings Release Q1 2023	2023-05-10	English
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory Earnings Release Q1 2023	2023-05-10	English
Lonza Announces Results of the 2023 Annual General Meeting All Motions Proposed by Board of Directors Accepted AGM Information	2023-05-05	English
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted AGM Information	2023-05-05	English
Lonza gibt Ergebnisse der Generalversammlung 2023 bekannt – Alle Anträge des Verwaltungsrats wurden angenommen AGM Information	2023-05-05	German
Lonza Increases Straight Bond by CHF 150 Million Capital/Financing Update	2023-04-20	English
Lonza Increases Straight Bond by CHF 150 Million Capital/Financing Update	2023-04-20	English
Lonza Launches Share Buyback Program of up to CHF 2 Billion Transaction in Own Shares	2023-03-31	English
Lonza Launches Share Buyback Program of up to CHF 2 Billion Transaction in Own Shares	2023-03-31	English
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) Regulatory Filings	2023-03-29	English
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) Regulatory Filings	2023-03-29	English
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports Report Publication Announcement	2023-03-27	English
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports AGM Information	2023-03-27	English
Lonza Completes Expansion of Conjugation Facility in Visp (CH) Regulatory Filings	2023-02-16	English
Lonza Completes Expansion of Conjugation Facility in Visp (CH) Regulatory Filings	2023-02-16	English
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon Capital/Financing Update	2023-02-08	English
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon Capital/Financing Update	2023-02-08	English
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin Earnings Release FY 2022	2023-01-25	English
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin Earnings Release FY 2022	2023-01-25	English
Lonza erzielt 2022 ein starkes Ergebnis mit 15.1% Umsatzwachstum (kWk) und 32.1% Kern-EBITDA-Marge Earnings Release FY 2022	2023-01-25	German